In myeloma, the combination of BRAF and MEK co‐inhibition (vemurafenib and cobimetinib, dabrafenib and trametinib) has been reported in four patients with advanced MM and BRAF p.V600E mutation and resulted in transient partial response [7, 8]. The gene discussed is BRAF; the disease is plasma cell myeloma.